NXY-059: a hopeful sign in the treatment of stroke.
Hess
David C
DC
Department of Neurology, Medical College of Georgia, Augusta, GA, USA. dhess@mail.mcg.edu
D000818:Animals; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D002144:Callithrix; D002719:Chlormethiazole / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000706:statistics & numerical data; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000473:pathology; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009589:Nitrogen Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D012107:Research Design; D012377:Rodentia; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D001557:Benzenesulfonates; D018691:Excitatory Amino Acid Antagonists; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D009589:Nitrogen Oxides; D011725:Pyridines; C096406:alpha-phenyl-2-pyridineethanamine dihydrochloride; D002719:Chlormethiazole; C120851:disufenton sodium; D010959:Tissue Plasminogen Activator